Effects of Z-100, a Mycobacterium-tuberculosis-derived arabinomannan, on the LP-BM5 murine leukemia virus infection in mice.
OBJECTIVE
To investigate the effects of Z-100, an arabinomannan extracted from Mycobacterium tuberculosis, on the LP-BM5 murine leukemia virus (LP-BM5 MuLV) infection in mice.


METHODS
C57BL/6 mice infected intraperitoneally with 4.5 x 10(2) PFU/mouse of LP-BM5 MuLV (MAIDS mice) were treated intraperitoneally with a 10-mg/kg dose of Z-100 every other day beginning 1 day after the viral infection. MAIDS mice treated with Z-100 were compared with control mice (MAIDS mice treated with saline) for their survival and splenomegaly after LP-BM5 infection. Cytokine-producing profiles of splenic T cells from these two groups of mice were also compared.


RESULTS
When MAIDS mice treated with Z-100 were compared with those of control mice, a decrease in splenomegaly and lymphadenopathy was observed. Splenomegaly was markedly enhanced in MAIDS mice treated intraperitoneally with IL-4 or IL-10. When MAIDS mice were treated with Z-100, their survival rates were significantly increased compared to those of controls. Splenic T cells from control mice produced type-2 cytokines (IL-4 and IL-10). However, a decreased production of type-2 cytokines by splenic T cells from MAIDS mice treated with Z-100 was demonstrated.


CONCLUSIONS
Z-100 could decrease the severity of the LP-BM5 MuLV infection through the regulation of MAIDS-associated type-2 T-cell responses.
Sasaki
H
H
Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555-0435, USA.
Kobayashi
M
M
Pollard
R B
RB
Suzuki
F
F
D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004336:Drug Antagonism; D016753:Interleukin-10 / Q000096:biosynthesis / Q000494:pharmacology; D015847:Interleukin-4 / Q000096:biosynthesis / Q000494:pharmacology; D009052:Leukemia Virus, Murine / Q000472:pathogenicity / Q000502:physiology*; D008055:Lipids / Q000627:therapeutic use*; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D016183:Murine Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality; D009929:Organ Size / Q000187:drug effects; D013047:Specific Pathogen-Free Organisms; D013154:Spleen / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013163:Splenomegaly / Q000188:drug therapy / Q000473:pathology; D015996:Survival Rate; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
D019380:Anti-HIV Agents; D008055:Lipids; D008351:Mannans; C031208:specific substance maruyama; D016753:Interleukin-10; D015847:Interleukin-4